Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2018, Article ID 1758383, 9 pages
https://doi.org/10.1155/2018/1758383
Research Article

Bushenkangshuai Tablet Reduces Atherosclerotic Lesion by Improving Blood Lipids Metabolism and Inhibiting Inflammatory Response via TLR4 and NF-κB Signaling Pathway

1First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
2Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
3Medical College, Xiamen University, Xiamen 361102, China

Correspondence should be addressed to Li Peng; moc.liamtoh@564gnepp and Jun-ping Zhang; moc.liamtoh@mcthz

Received 4 August 2017; Revised 6 November 2017; Accepted 10 December 2017; Published 24 January 2018

Academic Editor: Gorkem Kismali

Copyright © 2018 Shu-chao Pang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Ross, “Atherosclerosis—an inflammatory disease,” The New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. S. R. Smith, J. C. Lovejoy, F. Greenway et al., “Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity,” Metabolism - Clinical and Experimental, vol. 50, no. 4, pp. 425–435, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Hansen, H. Ahlström, S. Söderberg et al., “Visceral adipose tissue, adiponectin levels and insulin resistance are related to atherosclerosis as assessed by whole-body magnetic resonance angiography in an elderly population,” Atherosclerosis, vol. 205, no. 1, pp. 163–167, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Beltowski, “Leptin and atherosclerosis,” Atherosclerosis, vol. 189, no. 1, pp. 47–60, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. T. A. Hopkins, N. Ouchi, R. Shibata, and K. Walsh, “Adiponectin actions in the cardiovascular system,” Cardiovascular Research, vol. 74, no. 1, pp. 11–18, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Ouchi, S. Kihara, Y. Arita et al., “Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin,” Circulation, vol. 100, no. 25, pp. 2473–2476, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. C. X. Andersson, B. Gustafson, A. Hammarstedt, S. Hedjazifar, and U. Smith, “Inflamed adipose tissue, insulin resistance and vascular injury,” Diabetes/Metabolism Research and Reviews, vol. 24, no. 8, pp. 595–603, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Yamaguchi, J. G. M. Argueta, Y. Masuhiro et al., “Adiponectin inhibits Toll-like receptor family-induced signaling,” FEBS Letters, vol. 579, no. 30, pp. 6821–6826, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Li, Z. Wang, C. Wang, Q. Ma, and Y. Zhao, “Perivascular adipose tissue-derived adiponectin inhibits collar-induced carotid atherosclerosis by promoting macrophage autophagy,” PLoS ONE, vol. 10, no. 5, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Wang, X. N. Li, Y. Zou, and J. P. Zhang, “Clinical efficacy of bushen kangshuai tablet for unstable angina and effect on flammatory mediator in serum,” Chinese Journal of Experimental Traditional Medical Formulae, vol. 22, no. 14, pp. 171–176, 2016. View at Google Scholar
  11. Z. Q. Zhao, Q. Wang, C. Zhao et al., “Clinical study on bushen kangshuai tablets for treatment of angina pectoris of coronary heart disease with kidney deficiency and phlegm-stasis syndrome,” Chinese Journal of Integrative Medicine On Cardio/Cerebrovascular Disease, vol. 10, no. 9, pp. 1025–1027, 2012. View at Google Scholar
  12. J. Yue, B. Li, Q. Jing, and Q. Guan, “Salvianolic acid B accelerated ABCA1-dependent cholesterol efflux by targeting PPAR-γ and LXRα,” Biochemical and Biophysical Research Communications, vol. 462, no. 3, pp. 233–238, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. Q. Liu, J. Li, A. Hartstone-Rose et al., “Chinese herbal compounds for the prevention and treatment of atherosclerosis: experimental evidence and mechanisms,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 752610, 15 pages, 2015. View at Publisher · View at Google Scholar
  14. H. Miao, Y.-H. Zhao, N. D. Vaziri et al., “Lipidomics biomarkers of diet-induced hyperlipidemia and its treatment with poria cocos,” Journal of Agricultural and Food Chemistry, vol. 64, no. 4, pp. 969–979, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Li, Z. Chen, X. Mao, J. Yu, and R. Zhao, “Effects of lipid regulation using raw and processed radix polygoni multiflori in rats fed a high-fat diet,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 329171, 10 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. W.-G. Gwon, B. Lee, E.-J. Joung et al., “Sargaquinoic Acid Inhibits TNF-α-Induced NF-κB Signaling, Thereby Contributing to Decreased Monocyte Adhesion to Human Umbilical Vein Endothelial Cells (HUVECs),” Journal of Agricultural and Food Chemistry, vol. 63, no. 41, pp. 9053–9061, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. C.-Y. Liu, Y.-C. Lin, J.-S. Deng, J.-C. Liao, W.-H. Peng, and G.-J. Huang, “Antioxidant, anti-inflammatory, and antiproliferative activities of Taxillus sutchuenensis,” American Journal of Chinese Medicine, vol. 40, no. 2, pp. 335–348, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Ren, J. Hao, T. Liu et al., “Hesperetin Suppresses Inflammatory Responses in Lipopolysaccharide-Induced RAW 264.7 Cells via the Inhibition of NF-κB and Activation of Nrf2/HO-1 Pathways,” Inflammation, vol. 39, no. 3, pp. 964–973, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. S.-H. Kwon, S.-X. Ma, J.-Y. Hwang et al., “The anti-inflammatory activity of Eucommia ulmoides Oliv. Bark. involves NF-κB suppression and Nrf2-dependent HO-1 induction in BV-2 microglial cells,” Biomolecules & Therapeutics, vol. 24, no. 3, pp. 268–282, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Fazal, B. H. Abbasi, N. Ahmad, and M. Ali, “Elicitation of Medicinally Important Antioxidant Secondary Metabolites with Silver and Gold Nanoparticles in Callus Cultures of Prunella vulgaris L.,” Applied Biochemistry and Biotechnology, vol. 180, no. 6, pp. 1076–1092, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Donnapee, J. Li, X. Yang et al., “Cuscuta chinensis Lam.: a systematic review on ethnopharmacology, phytochemistry and pharmacology of an important traditional herbal medicine,” Journal of Ethnopharmacology, vol. 157, pp. 292–308, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. J.-P. Zhang, Y.-Z. Xu, and M. Li, “Effect of bushen kangshuai tablet on NF-kappaB signal pathway and inflammation factors in rabbits with experimental atherosclerosis,” Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi, vol. 29, no. 9, pp. 816–820, 2009. View at Google Scholar · View at Scopus
  23. L. Peng, C. Lv, Y. Zhao et al., “QiShenYiQi pill attenuates atherosclerosis by promoting regulatory T cells, inhibiting T helper 17 cells and accelerating cholesterol excretion,” Oncotarget, vol. 8, no. 47, pp. 82196–82206, 2017. View at Publisher · View at Google Scholar
  24. E. Alleva and D. Santucci, “Guide for the care and use of laboratory animals,” Ethology, vol. 103, no. 12, pp. 1072-1073, 1997. View at Publisher · View at Google Scholar
  25. A. A. Pendse, J. M. Arbones-Mainar, L. A. Johnson, M. K. Altenburg, and N. Maeda, “Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond,” Journal of Lipid Research, vol. 50, pp. S178–S182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. A. M. G. Cali, T. L. Zern, and S. E. Taksali, “Intrahepatic Fat Accumulation and Alterations in Lipoprotein Composition in Obese Adolescents,” Diabetes Care, vol. 30, no. 12, pp. 3093–3098, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Wieckowska, B. G. Papouchado, Z. Li, R. Lopez, N. N. Zein, and A. E. Feldstein, “Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis,” American Journal of Gastroenterology, vol. 103, no. 6, pp. 1372–1379, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Villanova, S. Moscatiello, S. Ramilli et al., “Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease,” Hepatology, vol. 42, no. 2, pp. 473–480, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. R. See, S. M. Abdullah, D. K. McGuire et al., “The association of differing measures of overweight and obesity with prevalent atherosclerosis. the dallas heart study,” Journal of the American College of Cardiology, vol. 50, no. 8, pp. 752–759, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. M. K. Öhman, Y. Shen, C. I. Obimba et al., “Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice,” Circulation, vol. 117, no. 6, pp. 798–805, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Okamoto, S. Kihara, N. Ouchi et al., “Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice,” Circulation, vol. 106, no. 22, pp. 2767–2770, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Persson, R. J. Strawbridge, S. E. Humphries et al., “Role of adiponectin in early atherosclerosis and incident cardiovascular disease in high-risk european subjects,” European Heart Journal, vol. 35, p. 611, 2014. View at Google Scholar
  33. X. Wang, Q. Chen, H. Pu et al., “Adiponectin improves NF-κB-mediated inflammation and abates atherosclerosis progression in apolipoprotein E-deficient mice,” Lipids in Health and Disease, vol. 15, no. 1, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. J.-E. Kim, S. E. Song, Y.-W. Kim et al., “Adiponectin inhibits palmitate-induced apoptosis through suppression of reactive oxygen species in endothelial cells: Involvement of cAMP/protein kinase A and AMP-activated protein kinase,” Journal of Endocrinology, vol. 207, no. 1, pp. 35–44, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Fairaq, N. M. Shawky, I. Osman, P. Pichavaram, and L. Segar, “AdipoRon, an adiponectin receptor agonist, attenuates PDGF-induced VSMC proliferation through inhibition of mTOR signaling independent of AMPK: Implications toward suppression of neointimal hyperplasia,” Pharmacological Research, vol. 119, pp. 289–302, 2017. View at Publisher · View at Google Scholar · View at Scopus
  36. A. R. Tall and L. Yvan-Charvet, “Cholesterol, inflammation and innate immunity,” Nature Reviews Immunology, vol. 15, no. 2, pp. 104–106, 2015. View at Publisher · View at Google Scholar · View at Scopus